Announced on October 15, 2026, the multi-year agreement gives California-based insitro a potential payday of about $1.5B as it works with AstraZeneca on drug discovery.
The deal includes a guaranteed $40M upfront payment and up to $1.46B in potential development and commercial milestones. insitro could also receive single-digit royalties on global product sales. Most of the headline value depends on future milestones, as Fierce Biotech reported.
Discovery work and worldwide rights
The companies will jointly identify drug targets for metabolic dysfunction-associated steatohepatitis, or MASH, a severe liver disease, and cardiomyopathies, a group of conditions affecting the heart muscle. They say both areas have significantly unmet medical needs.
insitro will use its Virtual Human AI platform to study disease biology and identify targets. AstraZeneca will nominate programs for the work to advance from discovery toward development candidates.
The platform combines machine learning with laboratory cell models, drawing on data from both insitro and AstraZeneca to connect biological mechanisms with potential therapeutic targets. The agreement starts at the discovery stage, rather than with a ready-made medicine. insitro will handle target discovery and early development. AstraZeneca will hold exclusive worldwide rights to selected programs and lead and fund later clinical trials. It will also handle regulatory work and commercialization, as Quartz reported.
That structure leaves discovery and early development with insitro, while AstraZeneca gets worldwide rights to selected programs for later-stage work. A separate discovery-stage deal, Pfizer’s Enodia agreement, also covers early research before the larger partner takes over development.
AstraZeneca’s wider deal activity
AstraZeneca is targeting $80B in revenue and 20 new medicines by 2030, putting the insitro agreement within a broader deal-making push.
Earlier this month, AstraZeneca and its Japanese partner Daiichi Sankyo reached a clinical trial collaboration with Summit Therapeutics. The Miami-based biotech received a $2B equity investment before the collaboration was announced.
